Treating Cells from the Inside Out
Revolutionising medicine with a new class of antibody drugs

Many diseases trace their root cause to problems within cells where some proteins can be synthesized incorrectly. Munich-based Mermaid Bio’s comes up with a completely new approach here combining two nano technologies.

One of these technologies is derived from alpaca antibodies and the other from the mRNA vaccine developed against the Coronavirus. It gives the body new tools to deal with cells that are making faulty or excessive proteins. This is the case with many cancers, neurological diseases or immunological conditions. This radical new approach lead to SPRIND now supporting Mermaid Bio on its ambitious agenda.

Mermaid Bio’s discovery process begins with an alpaca, which is exposed to copies of the protein of interest over a period of weeks. Once the alpaca’s immune system creates antibodies to bind to the protein, its new antibodies are isolated and simplified into “nanobodies”. Alpaca antibodies are a fraction of the size of a human antibody by nature, however just as powerful. Next, the nanobodies are encoded into RNA and loaded into lipid nanoparticles (LNPs). When these LNPs are injected into a patient, they are taken up within individual cells, which then produce copies of the nanobodies. At this point the nanobodies go to work, binding to the problematic protein and stopping it from causing the disease.
Co-Founder and Business Director Dr Chris Baldwin, Founder and Executive Director Dr Ranja Salvamoser and Science Director Assoc Prof Dr James Vince Co-Founder and Business Director Dr Chris Baldwin, Founder and Executive Director Dr Ranja Salvamoser and Science Director Assoc Prof Dr James Vince

SPRIND's funding allows to focus on innovating

In the laboratory, researchers have made nanobodies work inside cells for years, but this approach of using LNPs can open the door for their use with patients suffering from many illnesses. Before Mermaid Bio was established, its founders looked globally to find the ideal environment to support its innovative work as to make great leaps, start-ups need a wide range of assistance, from scientific expertise to funding opportunities. With the funding of SPRIND, Mermaid Bio can now continue focusing on innovating.
Mermaid Bio GmbH is on a mission to discover and develop breakthrough intrabodies, i.e. antibodies for intracellular targets, to treat unmet patient needs. Its method combines single domain antibodies (nanobodies) together with advancements in drug delivery by using mRNA/LNP systems to create a proprietary platform capable of producing breakthrough medicines.

Find more information about Mermaid Bio here.
Mermaid Bio